Tocilizumab for treating juvenile idiopathic arthritis

References

• Harrold LR, Salman C, Shoor S, et al. Incidence and prevalence of juvenile idiopathic arthritis among children in a managed care population, 1996-2009. J Rheumatol. 2013;40:1218–1225. doi:10.3899/jrheum.120661.
   PubMed Web of Science ®Google Scholar
• Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–392.
   PubMed Web of Science ®Google Scholar
• Martini A. Systemic juvenile idiopathic arthritis. Autoimmun Rev. 2012;12:56–59. doi:10.1016/j.autrev.2012.07.022.
   PubMed Web of Science ®Google Scholar
• Ravelli A, Magni-Manzoni S, Pistorio A, et al. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. J Pediatr. 2005;146:598–604. doi:10.1016/j.jpeds.2004.12.016.
   PubMed Web of Science ®Google Scholar
• Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74:1854–1860. doi:10.1136/annrheumdis-2014-205372.
   PubMed Web of Science ®Google Scholar
• Sen ES, Dick AD, Ramanan AV. Uveitis associated with juvenile idiopathic arthritis. Nat Rev Rheumatol. 2015;11:338–348. doi:10.1038/nrrheum.2015.20.
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum. 2007;56:647–657. doi:10.1002/art.22381.
   PubMed Web of Science ®Google Scholar
• Otten MH, Anink J, Prince FH, et al. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register. Ann Rheum Dis. 2015;74:1379–1386. doi:10.1136/annrheumdis-2013-204641.
   PubMed Web of Science ®Google Scholar
• Bingham C, Ardoin SP, Vora S, et al. A1: clinical inactive disease in the pediatric rheumatology care and outcomes improvement network cohort: which components of clinical inactive disease do patients not achieve? Arthritis Rheum. 2014;66:S1–S2. doi:10.1002/art.38412.
   Google Scholar
• Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2:288–294. doi:10.1158/2326-6066.CIR-14-0022.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012;52:199–219. doi:10.1146/annurev-pharmtox-010611-134715.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Robbioni P, et al. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991;34:1158–1163.
   PubMed Web of Science ®Google Scholar
• Pignatti P, Vivarelli M, Meazza C, et al. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J Rheumatol. 2001;28:1670–1676.
   PubMed Web of Science ®Google Scholar
• Rooney M, David J, Symons J, et al. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol. 1995;34:454–460.
   PubMedGoogle Scholar
• Boe A, Baiocchi M, Carbonatto M, et al. Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis. Cytokine. 1999;11:1057–1064. doi:10.1006/cyto.1999.0502.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102:1369–1376. doi:10.1172/JCI2629.
   PubMed Web of Science ®Google Scholar
• Schulert GS, Grom AA. Macrophage activation syndrome and cytokine-directed therapies. Best Pract Res Clin Rheumatol. 2014;28:277–292. doi:10.1016/j.berh.2014.03.002.
   PubMed Web of Science ®Google Scholar
• Strippoli R, Carvello F, Scianaro R, et al. Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum. 2012;64:1680–1688. doi:10.1002/art.33496.
   PubMed Web of Science ®Google Scholar
• Cifaldi L, Prencipe G, Caiello I, et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67:3037–3046. doi:10.1002/art.39295.
   PubMed Web of Science ®Google Scholar
• Scheller J, Chalaris A, Schmidt-Arras D, et al. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878–888. doi:10.1016/j.bbamcr.2011.01.034.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Massa M, Pignatti P, et al. Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis. J Clin Invest. 1994;93:2114–2119. doi:10.1172/JCI117206.
   PubMed Web of Science ®Google Scholar
• Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine. 2014;70:11–20. doi:10.1016/j.cyto.2014.05.024.
   PubMed Web of Science ®Google Scholar
• Jones SA, Richards PJ, Scheller J, et al. IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res. 2005;25:241–253. doi:10.1089/jir.2005.25.241.
   PubMed Web of Science ®Google Scholar
• Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53:851–856.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Narazaki M, Kishimoto T. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. FEBS Lett. 2011;585:3699–3709. doi:10.1016/j.febslet.2011.03.023.
   PubMed Web of Science ®Google Scholar
• Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5:1731–1740. doi:10.1016/j.intimp.2005.05.010.
   PubMed Web of Science ®Google Scholar
• Actemra (tocilizumab) injection, for intravenous use [Prescribing information]. South San Francisco (CA): Genentech; 2014. Available from: http://www.gene.com/download/pdf/actemra_prescribing.pdf
   Google Scholar
• Zhang X, Morcos PN, Saito T, et al. Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2013;6:123–137. doi:10.1586/ecp.13.1.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371:998–1006. doi:10.1016/S0140-6736(08)60454-7.
   PubMed Web of Science ®Google Scholar
• Zhang X, Morcos PN, De Benedetti F, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab (TCZ) in systemic juvenile idiopathic arthritis (sJIA). Clinical Pharmacology & Therapeutics. 2011;89:S36.
   Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2385–2395. doi:10.1056/NEJMoa1112802.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74:1110–1117. doi:10.1136/annrheumdis-2014-205351.
   PubMed Web of Science ®Google Scholar
• Decelle K, Horton ER. Tocilizumab for the treatment of juvenile idiopathic arthritis. Ann Pharmacother. 2012;46:822–829. doi:10.1345/aph.1Q756.
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky M, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66:1653–1661. doi:10.1002/acr.22384.
   PubMed Web of Science ®Google Scholar
• Uchiyama Y, Yoshida H, Koike N, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol. 2008;8:1595–1601. doi:10.1016/j.intimp.2008.07.002.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959–3964. doi:10.1182/blood-2008-05-155846.
   PubMed Web of Science ®Google Scholar
• Yokota S, Miyamae T, Imagawa T, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52:818–825. doi:10.1002/art.20944.
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan. J Rheumatol. 2014;41:759–767. doi:10.3899/jrheum.130690.
   PubMed Web of Science ®Google Scholar
• Woo P, Wilkinson N, Prieur AM, et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7:R1281–1288.
   PubMed Web of Science ®Google Scholar
• Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol. 2012;22:109–115. doi:10.1007/s10165-011-0481-0.
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Ruperto N, Giannini EH, et al. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9:557–563. doi:10.1038/nrrheum.2013.105.
   PubMed Web of Science ®Google Scholar
• Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum. 1997;40:1202–1209. doi:10.1002/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner H, Allen R, et al. Tocilizumab is efficacious in patients with systemic juvenile idiopathic arthritis across baseline demographic and disease characteristics and prior/baseline treatments: 52-week data from a phase 3 clinical trial. In: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals. Arthritis and Rheumatism. 2011;63(10 Suppl. 1).
   Google Scholar
• De Benedetti F, Ruperto N, Brunner H, et al. A6: tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER Study. Arthritis Rheum. 2014;66:S8–9. doi:10.1002/art.38417.
   Google Scholar
• De Benedetti F, Brunner H. FRI0328 Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): 2-year data from tender, a phase 3 clinical trial. Ann Rheum Dis. 2012;71:425. doi:10.1136/annrheumdis-2012-eular.2785.
   Web of Science ®Google Scholar
• De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67:840–848. doi:10.1002/art.38984.
   PubMed Web of Science ®Google Scholar
• Inaba Y, Ozawa R, Imagawa T, et al. Radiographic improvement of damaged large joints in children with systemic juvenile idiopathic arthritis following tocilizumab treatment. Ann Rheum Dis. 2011;70:1693–1695. doi:10.1136/ard.2010.145359.
   PubMed Web of Science ®Google Scholar
• Inaba Y, Ozawa R, Aoki C, et al. Radiologic analysis of the effect of tocilizumab on hands and large joints in children with systemic juvenile idiopathic arthritis. Mod Rheumatol. 2013;23:667–673. doi:10.1007/s10165-012-0711-0.
   PubMed Web of Science ®Google Scholar
• Aoki C, Inaba Y, Choe H, et al. Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis. J Rheumatol. 2014;41:1171–1177. doi:10.3899/jrheum.130924.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88–96. doi:10.1136/ard.2008.105197.
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72:43–50. doi:10.1136/annrheumdis-2011-201282.
   PubMed Web of Science ®Google Scholar
• Tozawa Y, Fujita S, Abe S, et al. Radiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis. Pediatr Int. 2015;57:307–310. doi:10.1111/ped.12454.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2015. doi:10.1136/annrheumdis-2015-207818. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Kessler EA, Vora SS, Verbsky JW. Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome. Pediatr Rheumatol Online J. 2012;10:30. doi:10.1186/1546-0096-10-24.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42:712–722. doi:10.3899/jrheum.140288.
   PubMed Web of Science ®Google Scholar
• Shimizu M, Nakagishi Y, Kasai K, et al. Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6. Cytokine. 2012;58:287–294. doi:10.1016/j.cyto.2012.02.006.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol. 2014;41:1163–1170. doi:10.3899/jrheum.131503.
   PubMed Web of Science ®Google Scholar
• Wallace CA, Ringold S, Bohnsack J, et al. Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis. J Rheumatol. 2014;41:2459–2465. doi:10.3899/jrheum.140347.
   PubMed Web of Science ®Google Scholar
• Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70:747–754. doi:10.1136/ard.2010.134254.
   PubMed Web of Science ®Google Scholar
• Gattorno M, Piccini A, Lasiglie D, et al. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2008;58:1505–1515. doi:10.1002/art.23437.
   PubMed Web of Science ®Google Scholar
• Sieper J, Porter-Brown B, Thompson L, et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis. 2014;73:95–100. doi:10.1136/annrheumdis-2013-203559.
   PubMed Web of Science ®Google Scholar
• Tsang AC, Roth J, Gottlieb C. Tocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patient. Ocul Immunol Inflamm. 2014;22:155–157. doi:10.3109/09273948.2013.866254.
   PubMed Web of Science ®Google Scholar
• Papo M, Bielefeld P, Vallet H, et al. Tocilizumab in severe and refractory non-infectious uveitis. Clin Exp Rheumatol. 2014;32:S75–79.
   PubMed Web of Science ®Google Scholar
• Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82. doi:10.1016/j.coi.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Bravo Mancheno B, Perin F, Guez Vazquez Del Rey MDM, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics. 2012;130:e1720–1724. doi:10.1542/peds.2012-1384.
   PubMed Web of Science ®Google Scholar
• Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum. 2015;44:472–475. doi:10.1016/j.semarthrit.2014.08.004.
   PubMed Web of Science ®Google Scholar
• Araki M, Matsuoka T, Miyamoto K, et al. Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology. 2014;82:1302–1306. doi:10.1212/WNL.0000000000000317.
   PubMed Web of Science ®Google Scholar